Physician profile
Racheed M Atassi
NPI 1710969639
$2,515.24
in general payments reported to CMS, 2019-2025
39 companies · $823 in 2025
The $823 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $87.15 · 2021: $249 · 2022: $492 · 2023: $159 · 2024: $513 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,405 · Debt Forgiveness: $90.37.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,404.93 |
| Debt Forgiveness | $90.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $353.53 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Corcept Therapeutics | $178.11 | 2025 | Korlym |
| Baxter Healthcare | $177.82 | 2022-2024 | |
| Lilly USA, LLC | $166.16 | 2020-2025 | Zepbound, Verzenio, Retevmo |
| Glaxosmithkline, LLC. | $153.40 | 2021-2025 | Trelegy Ellipta, Arexvy, Ojjaara |
| Boston Scientific Corporation | $149.98 | 2023-2024 | Watchman Flx |
| Otsuka America Pharmaceutical, INC. | $126.84 | 2025 | Rexulti |
| Medtronic, INC. | $121.97 | 2024 | Linq II |
| Janssen Pharmaceuticals, INC | $100.06 | 2019-2022 | |
| Amgen INC. | $94.72 | 2019-2023 | Repatha, Otezla |
| Pfizer INC. | $93.54 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $83.27 | 2024-2025 | Airsupra |
| E.R. Squibb & Sons, L.L.C. | $76.85 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $58.08 | 2021-2022 | |
| Dexcom, INC. | $46.94 | 2023-2024 | Dexcom G6 Transmitter |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Racheed Atassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.